US Pharma MarketingLegend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
Nine years after wowing the audience at the American Society of Clinical Oncol Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend Biotech’s scientific founder Frank Fan, M.D., Ph.D., is returning to the spotlight with an entirely new playbook. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special…
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend Biotech’s scientific founder Frank Fan, M.D., Ph.D., is returning to the spotlight with an entirely new playbook.
Source: FierceBiotech